BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
05/25/2023
Resolution
06/15/2023
This is a confidential investigation of certain directors & officers of ChromaDex Corporation (CDXC) regarding a potential breach of fiduciary duties to the company and its shareholders.
ChromaDex Corporation (CDXC) investors and shareholders are invited to contact the law firm below for additional information.
Brios is not a law firm and does not make any representation or judgment as to the qualifications, expertise, or credentials of any law firm advertising on our website, please refer to our terms and conditions for further information.
04/28/2023
ChromaDex Corporation (CDXC) files its proxy statement with the SEC for its 2023 annual meeting to be held on Thursday, June 15, 2023.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$1.34 | $1.32 | $0.02 | 1.52% |
We have marked this investigation as closed.
The stockholders annual meeting took place.
On 06/15/2023 the company issued the following statement:
N/A
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.